NASDAQ:VCEL Vericel Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vericel Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.12 +0.14 (+0.74 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$18.60Now: $19.12▼$19.5850-Day Range$15.17MA: $16.39▼$18.9852-Week Range$6.78Now: $19.12▼$19.64Volume1.81 million shsAverage Volume671,574 shsMarket Capitalization$865.18 millionP/E RatioN/ADividend YieldN/ABeta2.88 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.20, Vericel has a forecasted upside of 26.6% from its current price of $19.12.Amount of Analyst CoverageVericel has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.4 Community Rank Outperform VotesVericel has received 301 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVericel has received 323 “underperform” votes. (Add your “underperform” vote.)Community SentimentVericel has received 51.76% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote “Outperform” if you believe VCEL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $221,413.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Vericel is held by insiders.Percentage Held by Institutions94.98% of the stock of Vericel is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow in the coming year, from ($0.17) to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -1,912.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -1,912.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.69 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCEL Previous Symbol CUSIPN/A CIK887359 Webwww.vcel.com Phone617-588-5555Debt Debt-to-Equity Ratio0.19 Current Ratio6.39 Quick Ratio5.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$117.85 million Price / Sales7.34 Cash Flow$0.22 per share Price / Cash Flow85.51 Book Value$2.49 per share Price / Book7.68Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees216 Outstanding Shares45,250,000Market Cap$865.18 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $19.12 +0.14 (+0.74 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VCEL News and Ratings via Email Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Vericel (NASDAQ:VCEL) Frequently Asked Questions How has Vericel's stock been impacted by Coronavirus (COVID-19)? Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VCEL stock has increased by 58.3% and is now trading at $19.12. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Vericel? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vericel. When is Vericel's next earnings date? Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Vericel. How were Vericel's earnings last quarter? Vericel Corp (NASDAQ:VCEL) released its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.03. The biotechnology company had revenue of $20 million for the quarter, compared to the consensus estimate of $19.31 million. The business's quarterly revenue was down 23.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.05) EPS. View Vericel's earnings history. What guidance has Vericel issued on next quarter's earnings? Vericel issued an update on its second quarter 2020 Pre-Market earnings guidance on Thursday, July, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $15.79 million. What price target have analysts set for VCEL? 6 Wall Street analysts have issued 12-month price targets for Vericel's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Vericel's stock price to reach $24.20 in the next year. This suggests a possible upside of 26.6% from the stock's current price. View analysts' price targets for Vericel. Who are some of Vericel's key competitors? Some companies that are related to Vericel include Fate Therapeutics (FATE), Immunovant (IMVT), Twist Bioscience (TWST), Legend Biotech (PCVX), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), Revolution Medicines (RVMD), BAVARIAN NORDIC/S (BVNRY), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Sangamo Therapeutics (SGMO) and Beam Therapeutics (BEAM). View all competitors. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Momo (MOMO), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Amarin (AMRN), TG Therapeutics (TGTX) and Verastem (VSTM). Who are Vericel's key executives? Vericel's management team includes the following people: Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 55)Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 56)Mr. Daniel R. Orlando, Chief Operating Officer (Age 54)Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.Ms. Heidi Hassen, Sr. Director of HR What is Vericel's stock symbol? Vericel trades on the NASDAQ under the ticker symbol "VCEL." Who are Vericel's major shareholders? Vericel's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RTW Investments LP (8.51%), Deerfield Management Company L.P. Series C (6.76%), Vanguard Group Inc. (5.26%), Great Point Partners LLC (3.56%), Kopp Family Office LLC (2.39%) and Fort Washington Investment Advisors Inc. OH (1.55%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View institutional ownership trends for Vericel. Which major investors are selling Vericel stock? VCEL stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Deerfield Management Company L.P. Series C, RTW Investments LP, Emerald Advisers LLC, Nuveen Asset Management LLC, Marshall Wace LLP, Silvercrest Asset Management Group LLC, and Vanguard Group Inc.. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, and Michael Halpin. View insider buying and selling activity for Vericel. Which major investors are buying Vericel stock? VCEL stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, New York State Common Retirement Fund, Summit Creek Advisors LLC, Kopp Family Office LLC, Prosight Management LP, Cadence Capital Management LLC, Two Sigma Advisers LP, and Goldman Sachs Group Inc.. View insider buying and selling activity for Vericel. How do I buy shares of Vericel? Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vericel's stock price today? One share of VCEL stock can currently be purchased for approximately $19.12. How big of a company is Vericel? Vericel has a market capitalization of $865.18 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe. What is Vericel's official website? The official website for Vericel is www.vcel.com. How can I contact Vericel? Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
